Authors: Vermorken, JB Zanetta, G Oliveira, CFD van der Burg, MEL Lacave, AJ Teodorovic, I Boes, GH Colombo, N

Citation: Jb. Vermorken et al., Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma ofthe uterine cervix: An EORTC Gynecological Cancer Cooperative Group study, ANN ONCOL, 12(7), 2001, pp. 967-974

Authors: Hamilton, A Roy, JA Beex, L Piccart, M Mauriac, L Coleman, R Paridaens, R Boes, GH van Vreckem, A Palmer, P Klijn, J

Citation: A. Hamilton et al., EORTC 10941: A phase II study of liarozole in postmenopausal patients with'Chemotherapy-Resistant' or 'Potentially Hormone Sensitive' metastatic breast cancer, BREAST CANC, 60(2), 2000, pp. 181-188

Authors: Curran, D Sylvester, RJ Boes, GH

Citation: D. Curran et al., Sample size estimation in phase III cancer clinical trials, EUR J SUR O, 25(3), 1999, pp. 244-250

Authors: Pawinski, A Tumolo, S Hoesel, G Cervantes, A van Oosterom, AT Boes, GH Pecorelli, S

Citation: A. Pawinski et al., Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group, EUR J OB GY, 86(2), 1999, pp. 179-183